Investigational drug · Phase 3
tabelecleucel
Also called: ATA129, EBV-CTLs
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
17
Any phase or sponsor naming "tabelecleucel"
First trial start
2017
Dec 29, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "tabelecleucel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Organ Transplant Complications
- Lymphoproliferative Disorders
- Allogeneic Hematopoietic Cell Transplant
- Stem Cell Transplant Complications
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Epstein-Barr Virus (EBV)-Associated Diseases
- EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)
- EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)
- EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
- EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "tabelecleucel" as an intervention, largest first.
- A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated DiseasesActive, not recruiting
Pierre Fabre MedicamentIndustry
NCT04554914 · 190 participants (planned) · Start Jul 14, 2021 · Primary completion Jun 2027
Drug: Tabelecleucel · For: Epstein-Barr Virus (EBV)-Associated Diseases; EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD); EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD) and 8 more
Sites: Los Angeles, California; Orange, California; Palo Alto, California · 40 sites in all
- Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple SclerosisPivotal-lookingTerminated
Atara BiotherapeuticsIndustry
NCT03283826 · 134 participants · Start Oct 19, 2017 · Primary completion Nov 9, 2023
Drug: ATA188; Placebo · For: Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis
Sites: La Jolla, California; Los Angeles, California; Palo Alto, California · 31 sites in all
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyPivotal-lookingRecruiting
Pierre Fabre MedicamentIndustry
NCT03394365 · 115 participants (planned) · Start Dec 29, 2017 · Primary completion May 31, 2030
Drug: tabelecleucel · For: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Solid Organ Transplant Complications; Lymphoproliferative Disorders and 2 more
Sites: Duarte, California; La Jolla, California; Loma Linda, California · 71 sites in all
Atara BiotherapeuticsIndustry
NCT01498484 · 87 participants · Start Dec 2011 · Primary completion Jul 2019
Drug: EBV-specific T cells (EBV-CTLs) · For: EBV-induced Lymphomas; EBV-associated Malignancies; Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Sites: New York, New York
Atara BiotherapeuticsIndustry
NCT00002663 · 58 participants · Start Mar 1995 · Primary completion Jul 2019
Drug: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) · For: EBV-induced Lymphomas; EBV-associated Malignancies; Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Sites: New York, New York
Baylor College of MedicineAcademic, hospital or other
NCT00889954 · 20 participants · Start May 2009 · Primary completion Jul 2015
Drug: TGFBeta resistant HER2/EBV-CTLs · For: HER2 Positive Malignancies
Sites: Houston, Texas · 2 sites in all
Baylor College of MedicineAcademic, hospital or other
NCT00953420 · 20 participants · Start Nov 2009 · Primary completion Jun 2014
Drug: Docetaxel; Carboplatin and 3 more · For: Nasopharyngeal Carcinoma
Sites: Houston, Texas · 3 sites in all
New York Medical CollegeAcademic, hospital or other
NCT03266653 · 20 participants (planned) · Start Jul 7, 2020 · Primary completion Dec 31, 2026
Drug: cytotoxic t-lymphocytes · For: Epstein-Barr Virus Infections; Primary Immune Deficiency Disorder
Sites: Los Angeles, California; San Francisco, California; Baltimore, Maryland · 8 sites in all
- PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated MalignanciesStatus unknown
Yang YangAcademic, hospital or other
NCT03044743 · 20 participants (planned) · Start Apr 7, 2017 · Primary completion Mar 2020
Drug: Fludarabine; Cyclophosphamide and 1 more · For: Stage IV Gastric Carcinoma; Stage IV Nasopharyngeal Carcinoma; T-Cell Lymphoma Stage IV and 2 more
Sites: Nanjing, China · 2 sites in all
- In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell MalignanciesActive, not recruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT01430390 · 19 participants · Start Sep 2011 · Primary completion Sep 2027
Drug: Biological/Genetically Modified T cells; Cyclophosphamide-based chemotherapy · For: Acute Lymphocytic Leukemia; Lymphoma
Sites: New York, New York
Newest research
PubMed records naming it or its code names, newest first.
- Recognition and management of early complications in CAR-T cell therapy and virus-specific T-lymphocyte therapy: a practical clinical reference.
Ussowicz M, Jakubczyk E, Wróbel T, et al. · Front Immunol 2026
- Post-transplant lymphoproliferative disorder after solid organ transplantation: a comprehensive review.
Vargas-Nieto LP, Santoyo-Sarmiento ND, Ballesteros-García M, et al. · Front Transplant 2026
- Case Report: Hyperinflammatory toxicities after Epstein-Barr virus-associated post-transplant lymphoproliferative disorder and hemophagocytic lymphohistiocytosis in a pediatric kidney transplant recipient.
Ussowicz M, Jarmużek W, Rutynowska-Pronicka O, et al. · Front Immunol 2026
- Real-world experience with tabelecleucel.
Nagler A · Blood Adv 2026
- Real-world experience with tabelecleucel within and beyond the approval label.
Farid KMN, Kocher F, Arnold T, et al. · Blood Adv 2026
- RNA Sequencing Analyses and Validation of Immune-Related Genes in EBV-Specific Cytotoxic T Lymphocytes During Latent Infection.
Guan Z, Ao X, Zhou L, et al. · Immunotargets Ther 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.